Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies
暂无分享,去创建一个
Lynn Morris | Chaim A. Schramm | John R Mascola | Jason Gorman | Lawrence Shapiro | Peter D Kwong | Penny L Moore | Gordon Botha | J. Mascola | L. Morris | N. Doria-Rose | L. Shapiro | P. Kwong | J. Gorman | P. Moore | J. Bhiman | N. Garrett | C. Williamson | S. A. Abdool Karim | Chaim A Schramm | Jinal N Bhiman | Colin Anthony | Nicole A Doria-Rose | Owen Karimanzira | Thandeka Khoza | Dale Kitchin | Nigel J Garrett | Salim S Abdool Karim | Carolyn Williamson | T. Khoza | C. Anthony | G. Botha | D. Kitchin | Owen Karimanzira
[1] Chaim A. Schramm,et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.
[2] Richard T. Wyatt,et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.
[3] A. Brink. The South African Medical Research Council , 1973 .
[4] J. Sodroski,et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization , 1996, Journal of virology.
[5] Florian Klein,et al. Antibodies in HIV-1 Vaccine Development and Therapy , 2013, Science.
[6] L. Morris,et al. Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes , 2013, PLoS pathogens.
[7] Daniel J. Blankenberg,et al. Galaxy: A Web‐Based Genome Analysis Tool for Experimentalists , 2010, Current protocols in molecular biology.
[8] B. Korber,et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection , 2014, AIDS.
[9] C. Gray,et al. Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study , 2008, PloS one.
[10] Feng Gao,et al. Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies , 2014, Cell.
[11] M. Nussenzweig,et al. Predominant Autoantibody Production by Early Human B Cell Precursors , 2003, Science.
[12] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[13] John D. Hunter,et al. Matplotlib: A 2D Graphics Environment , 2007, Computing in Science & Engineering.
[14] K. Katoh,et al. MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.
[15] Lynn Morris,et al. Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.
[16] S. Segawa,et al. End of the beginning , 1990, Nature.
[17] T. A. Hall,et al. BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT , 1999 .
[18] James E. Crowe,et al. Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes , 2012, PloS one.
[19] A. Nekrutenko,et al. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences , 2010, Genome Biology.
[20] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[21] L. Morris,et al. Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies , 2013, Journal of Virology.
[22] Cassandra B. Jabara,et al. Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID , 2011, Proceedings of the National Academy of Sciences.
[23] David Nemazee,et al. Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.
[24] Robert C. Edgar,et al. MUSCLE: multiple sequence alignment with high accuracy and high throughput. , 2004, Nucleic acids research.
[25] Anton Nekrutenko,et al. Manipulation of FASTQ data with Galaxy , 2010, Bioinform..
[26] W. Delano. The PyMOL Molecular Graphics System , 2002 .
[27] Lynn Morris,et al. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency , 2015, Journal of Virology.
[28] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[29] G. Shaw,et al. A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays. , 2010, Virology.
[30] J. Mascola,et al. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning , 2013, Nature Reviews Immunology.
[31] K. Katoh,et al. Improvements in Performance and Usability , 2013 .
[32] Daniel J. Blankenberg,et al. Galaxy: a platform for interactive large-scale genome analysis. , 2005, Genome research.
[33] J. Baeten,et al. Breadth of Neutralizing Antibody Response to Human Immunodeficiency Virus Type 1 Is Affected by Factors Early in Infection but Does Not Influence Disease Progression , 2009, Journal of Virology.
[34] Dennis R. Burton,et al. A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.
[35] John P. Moore,et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex , 2014, Proceedings of the National Academy of Sciences.
[36] S. Travers,et al. RAMICS: trainable, high-speed and biologically relevant alignment of high-throughput sequencing reads to coding DNA , 2014, Nucleic acids research.
[37] L. Morris,et al. The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.
[38] H. Schuitemaker,et al. Longitudinal Analysis of Early HIV-1-Specific Neutralizing Activity in an Elite Neutralizer and in Five Patients Who Developed Cross-Reactive Neutralizing Activity , 2011, Journal of Virology.
[39] B. Korber,et al. Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing , 2008, Journal of Virology.
[40] Qing Zhu,et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations , 2014, Nature.
[41] Xuesong Yu,et al. Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.
[42] M. Nussenzweig,et al. Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses , 2011, PloS one.
[43] B. Haynes,et al. HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.
[44] Chaim A. Schramm,et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.
[45] L. Stamatatos,et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.